ROCKVILLE, Md., Sept. 12 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD - News), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced commencement of a multi-center Phase 2 study with its lead clinical- stage drug candidate, Panzem® NCD (2ME2 or 2-methoxyestradiol), in patients with hormone-refractory prostate cancer (HRPC). Initially, the study will be conducted by the University of Wisconsin Comprehensive Cancer Center, as a member of the Prostate Cancer Clinical Trial Consortium, with additional sites joining during the third quarter. Dr. Glenn Liu, Assistant Professor of Medicine, University of Wisconsin, will serve as the principal investigator.
